CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Delabeling for Penicillin Allergy Found Safe in Children

Published: Fri, 20 Apr 2018 08:02:52 EDT
Children with low-risk penicillin allergy symptoms who tested negative for penicillin allergy tolerated penicillin without serious adverse or allergic reactions during the following year, a study found.
Medscape Medical News

CMS Should Have Required a Randomized Trial of F1CDx

Published: Fri, 20 Apr 2018 12:00:00 EDT
Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
Annals of Oncology
Displaying results 19-20 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Basilea slots ArQule FGF drug into its cancer portfolio

Published: Tue, 17 Apr 2018 12:50:57 +0000
Deal-hungry Basilea has extended its cancer pipeline by licensing ArQule’s derazantinib, a phase 2-ready drug that slots in ahead of its in-house oncology programs.

J&J buys into Bristol-Myers cardiovascular disease program

Published: Tue, 17 Apr 2018 12:09:41 +0000
Johnson & Johnson has bought into Bristol-Myers Squibb’s Factor XIa inhibitor program. The deal gives J&J a stake in the development and potential commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Johnson & Johnson says it has 15% more to splash on R&D thanks to tax cuts. Will we see more pipeline plays?

Published: Tue, 17 Apr 2018 11:14:14 +0000
Share buybacks have been the name of the game for a few years now as M&A went through a quiet patch, but with deals ramping up in 2018, Johnson & Johnson says it's boosting its R&D budget over the coming years. Will the Big Pharma be looking to beef up its pipeline?
Displaying results 19-21 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top